Dactinomycin Alternatives Compared
| Dactinomycin | Meloxicam | Celebrex (celecoxib) |
|
|---|
| Dactinomycin | Meloxicam | Celebrex (celecoxib) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ewing's Sarcoma, Cancer, Osteoarthritis, Osteosarcoma, Ovarian Cancer, Rhabdomyosarcoma, Testicular Cancer, Trophoblastic Disease, Wilms' Tumor. Dactinomycin may also be used for... View more |
Prescription only
Meloxicam is effective for the short-term relief of pain and inflammation associated with arthritis; however, like other NSAIDs, it has the potential to adversely affect the stomach or heart and... View more |
Prescription only
Celebrex is a COX-2-specific NSAID that is used to manage the signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis. It is also used... View more |
Related suggestions Osteoarthritis
|
|||||||||||||||||||||||
| More about Dactinomycin | More about Meloxicam | More about Celebrex (celecoxib) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Meloxicam has an average rating of 6.3 out of 10 from a total of 603 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 33% reported a negative effect. |
Celebrex has an average rating of 7.0 out of 10 from a total of 226 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 23% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Dactinomycin side effects |
View all Meloxicam side effects |
View all Celebrex side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Dactinomycin prices |
View all Meloxicam prices |
View all Celebrex prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Cosmegen | Qamzova, Xifyrm | Other celecoxib brands include: Elyxyb, Vyscoxa | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
36 hours |
20 hours |
11 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
Prior To 30 Weeks Gestation
Category D
Positive evidence of risk
Starting At 30 Weeks Gestation See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
Prior To 30 Weeks Gestation
Category D
Positive evidence of risk
Starting At 30 Weeks Gestation See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 252 drugs are known to interact with Dactinomycin:
|
A total of 473 drugs are known to interact with Meloxicam:
|
A total of 461 drugs are known to interact with Celebrex:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 10, 1964 |
April 13, 2000 |
December 31, 1998 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.